Multiple MyelomaPhase 2IFM 2024_06NCT06931704
Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
A Phase 2 study testing Elranatamab, Daratumumab and Lenalidomide in people with Multiple Myeloma, run by Nantes University Hospital at 36 sites in France.
Trial summary
Lenalidomide is a standard of care for maintenance therapy after autologous stem cell transplantation in newly diagnosed myeloma patients. Recently, two large phase 3 randomized trials demonstrated a progression free survival benefit with daratumumab maintenance post autologous stem cell transplantation. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multiple Myeloma
- What is being tested?
- Elranatamab, Daratumumab and Lenalidomide
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 176 participants
- Where
- 36 sitesFrance
- Study dates
- 1 May 2025to 30 Nov 2031
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- - Male or female subjects, 18 years of age or older
- - Voluntary written informed consent must be given before performance of any study-related procedure not part of normal medical care, with the understanding that the subject may withdraw consent at any time without prejudice to future medical care.
- - Subject must have documented multiple myeloma according to International Myeloma Working Group (IMWG) criteria and have received 4 to 6 cycles of quadruplet-based therapy including proteasome inhibitor, IMID and anti CD38 monoclonal antibody.
- - Subject must have received only one line of therapy and achieved at least a partial response as per IMWG 2016 criteria.
- - Subject must have received high-dose melphalan and ASCT within 12 months of the start of induction therapy and be within 6 months of the last ASCT at the time of first treatment dose.
- - Subject must have NGS analysis performed at time of MM diagnosis and/or adequate stored bone marrow material allowing NGS analysis (IUCT-Oncopole, Toulouse, France) in order to calibrate MRD analysis.
Show all 12Show fewer
- - Karnofsky performance status score ≥ 50% (eastern cooperative oncology group performance status ECOG score ≤ 2).
- - Subject must have clinical laboratory values meeting the following criteria during the Screening Phase:
- Hematology : Hemoglobin >8.0 g/dL without prior RBC transfusion within 7 days before the laboratory test; recombinant human erythropoietin use is permitted) + Platelets ≥75×109/L (without transfusion support or thrombopoietin receptor agonist within 7 days before the laboratory test) + Absolute neutrophil count ≥1.0×109/L (prior growth factor support is permitted but must be without support for 7 days for G-CSF or 14 days for pegylated-G-CSF)
- Chemistry : AST and ALT ≤2.5× upper limit of normal (ULN) + CrCl ≥30 mL/min based on Cockroft-Gault formula calculation or a 24-hour urine collection + Total bilirubin ≤1.5×ULN; except in participants with congenital bilirubinemia, such as Gilbert syndrome (in which case direct bilirubin ≤1.5×ULN is required) + Serum calcium corrected for albumin ≤14 mg/dL (≤3.5 mmol/L)
- - Women of childbearing potential must have a negative serum or urine pregnancy test within 10 to 14 days prior to therapy and repeated within 24 hours before starting study drug. They must commit to continued abstinence from heterosexual intercourse or begin 2 acceptable methods of birth control (One highly effective method and one additional effective method) used at the same time, beginning at least 4 weeks before initiation of lenalidomide treatment and continuing for at least 6 months after the last dose of Lenalidomide or Elranatamab depending on the last treatment taken. Highly effective contraceptive methods are defined as any of the following methods: combined hormonal contraception (containing estrogen and progestin) combined with ovulation inhibition (oral, intravaginal, transdermal), progestin-only hormonal contraception combined with ovulation inhibition (oral, injectable, implantable), intrauterine device (IUD), hormone-releasing intrauterine system (IUS), bilateral tubal occlusion, vasectomised partner, sexual abstinence.Women must also agree to notify pregnancy during the study.
- - Men must agree to not father a child and agree to use a latex condom during therapy and for 6 months after the last dose of study drug, even if they have had a successful vasectomy, if their partner is of childbearing potential.
Who cannot join
- - Subjects have received any prior anti BCMA therapy.
- - Subject have received post transplantation maintenance therapy.
- - Subject intolerant to lenalidomide or have discontinued treatment due to any AE related to lenalidomide.
- - Subject is exhibiting clinical signs of meningeal involvement of multiple myeloma.
- - Myocardial infarction within 6 months prior to enrollment according to NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
- - Uncontrolled hypertension.
Show all 30Show fewer
- - Subjects with known chronic obstructive pulmonary disease (COPD) with a Forced Expiratory Volume in 1 second (FEV1) < 50% of predicted normal. Note that FEV1 testing is required for patients suspected of having COPD and subjects must be excluded if FEV1 < 50% of predicted normal.
- - Subjects with a history of moderate or severe persistent asthma within the past 2 years, or with uncontrolled asthma of any classification at the time of screening (Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study).
- - Subject has plasma cell leukemia (according to WHO criterion: ≥ 20% of cells in the peripheral blood with an absolute plasma cell count of more than 2 × 109/L) or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
- - Systemic treatment with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort within 14 days before the first dose of study treatment.
- - Known intolerance to steroid therapy.
- - History of allergy to any of the study medications, their analogues, or excipients in the various formulations.
- - Subject has had major surgery within 2 weeks before randomization or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study. Kyphoplasty or Vertebroplasty are not considered major surgery.
- - Clinically relevant active infection or serious co-morbid medical conditions.
- - Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical, breast or prostate cancer free of disease since 5 years.
- - Female subject who is pregnant or breast-feeding.
- - Serious medical or psychiatric illness likely to interfere with participation in study.
- - Uncontrolled diabetes mellitus.
- - Active HBV, HCV, SARS-CoV-2, HIV, or any active, uncontrolled bacterial, fungal, or viral infection. Active infections must be resolved at least 21 days prior to enrollment. Treatment with systemic anti-infective agents must have completed at least 28 days prior to enrollment. Prophylactic use of systemic agents is permitted.
- COVID-19/SARS-CoV-2: SARS-CoV-2 PCR testing is mandated within 5 days prior to enrollment. Participants with positive PCR test result for SARS-CoV-2 within 5 days prior to enrollment, or suspected of having SARS-CoV-2, are excluded.
- HIV: In equivocal cases, participants whose viral load is negative may be eligible. HIV seropositive participants who are otherwise healthy and at low risk for AIDS-related outcomes could be considered eligible. Potential eligibility for a specific HIV positive protocol candidate should be evaluated and discussed with the sponsor prior to screening, considering current and past CD4+ and T-cell counts, history (if any) of AIDS defining conditions (eg, opportunistic infections), status of HIV treatment and the potential for drug-drug interactions.
- HBV:
- Participants with a positive HBsAg test (ie, either acute or chronic active hepatitis) are excluded.
- Participants with HBV antibody positivity indicating immunity, either due to vaccination or prior natural infection, are eligible.
- Participants with positive anti-HBcAb but negative HBsAg and negative anti-HBsAb profile are eligible if HBV DNA is not detected.
- For additional details, refer to CDC website (https://www.cdc.gov/hepatitis/HBV/PDFs/SerologicChartv8.pdf).
- HCV: Positive HCV antibody is indicative of infection but may not necessarily render a potential candidate ineligible, depending on clinical circumstances. If exposure to HCV is recent, HCV antibody may not have yet turned positive. In these circumstances it is recommended to test for HCV RNA. If HCV RNA is detected, the patient is not eligible. Refer to CDC website for further details(https://www.cdc.gov/hepatitis/hcv/pdfs/hcv_graph.pdf).
- - Incidence of gastrointestinal disease that may significantly alter the absorption of oral drugs.
- - Subjects unable or unwilling to undergo antithrombotic prophylactic treatment.
- - Person under guardianship, trusteeship or deprived of freedom by a judicial or administrative decision.
Trial locations and contacts
36 sites in 1 country. Contact the study team or a site near you to ask about taking part.
36 sites in 1 country
France36 sites
CHU Angers
Angers
Mammoun DIB, 02 41 35 47 05 ext. +33, MaDib@chu-angers.fr
CH Côte Basque
Bayonne
Julie GAY, 05 59 44 38 32 ext. +33, jgay@ch-cotebasque.fr
CHU Besançon
Besançon
Jean FONTAN, 03 81 66 82 32 ext. +33, jfontan@chu-besancon.fr
CHU Caen
Caen
Margaret MACRO, 02 31 27 21 22 ext. +33, macro-m@chu-caen.fr
Hôpital d'Instruction des Armées Percy
Clamart
Jean MAILLOT, 01 41 46 63 01 ext. +33, jean.maillot@intradef.gouv.fr
CHU Clermont- Ferrand - Hôpital ESTAING
Clermont-Ferrand
Carine CHALETEIX, 04 73 75 00 65 ext. +33, cchaleteix@chu-clermontferrand.fr
Hôpital Henri Mondor
Créteil
Romain GOUNOT, 01 49 81 43 20 ext. +33, romain.gounot@aphp.fr
CHRU Dijon
Dijon
Andrea PIERAGOSTINI, 03 80 29 50 41 ext. +33, andrea.pieragostini@chu-dijon.fr
Institut de cancérologie de Bourgogne
Dijon
Marie-Lorraine CHRETIEN-MEURIOT, 03 80 29 45 06 ext. +33, mlchretien@icb-cancer.fr
Hôpital Annecy Genevois
Épagny
Frédérique ORSINI-PIOCELLE, 04 50 63 66 08 ext. +33, forsinipiocelle@ch-annecygenevois.fr
CHD Vendée
La Roche-sur-Yon
Komivi AGBETSIVI, 02 51 44 61 73 ext. +33, komivi.agbetsivi@chd-vendee.fr
CH Le Mans - Centre de cancérologie de la Sarthe
Le Mans
Kamel LARIBI, 02 55 46 34 67 ext. +33, klaribi@ch-lemans.fr
CH de Libourne
Libourne
Elodie SCHERMAN, 05 57 55 26 17 ext. +33, elodie.scherman@ch-libourne.fr
CHU Limoges
Limoges
Murielle ROUSSEL, 05 55 05 66 51 ext. +33, murielle.roussel@chu-limoges.fr
Groupement Hospitalier Bretagne Sud
Lorient
Adrien TREBOUET, 02 97 06 91 85 ext. +33, a.trebouet@ghbs.bzh
Centre Léon BERARD
Lyon
Philippe REY, 04 26 55 67 95 ext. +33, philippe.rey@lyon.unicancer.fr
IPC Marseille
Marseille
Jean-Marc SCHIANO DE COLELLA, 04 91 22 38 66 ext. +33, schianodecolella@ipc.unicancer.fr
CHRU Nancy
Nancy
Caroline JACQUET, 03 83 15 52 49 ext. +33, c.jacquet@chru-nancy.fr
CHU Nantes
Nantes
Cyrille TOUZEAU, 02 40 08 32 71 ext. +33, cyrille.touzeau@chu-nantes.fr
CHU de Nice - Hôpital l'Archet 1
Nice
Valentine RICHEZ-OLIVIER, 04 92 03 58 41 ext. +33, richez-olivier.v@chu-nice.fr
CHU de Nîmes - Institut de Cancérologie du Gard
Nîmes
Nicolas BRANCHE, 04 66 68 40 33 ext. +33, nicolas.branche@chu-nimes.fr
Hopital St Louis
Paris
Bertrand ARNULF, 01 42 49 94 72 ext. +33, bertrand.arnulf@sls.aphp.fr
Hôpital Cochin
Paris
Marguerite VIGNON, 01 58 41 21 10 ext. +33, marguerite.vignon@aphp.fr
Hôpital Necker
Paris
Laurent FRENKEL, 01 44 49 52 92 ext. +33, laurent.frenzel@aphp.fr
Hôpital St Antoine
Paris
Mohamad MOHTY, 01 49 28 26 24 ext. +33, mohamad.mohty@inserm.fr
CH Périgueux
Périgueux
Claire CALMETTES, 05 53 45 25 85 ext. +33, claire.calmettes@ch-perigueux.fr
CH Saint-Jean
Perpignan
Virginie ROLAND, 04 68 61 89 07 ext. +33, virginie.roland@ch-perpignan.fr
CHRU - Hôpital du Haut Lévêque
Pessac
Cyrille HULIN, 05 57 65 65 11 ext. +33, cyrille.hulin@chu-bordeaux.fr
CHU de Poitiers
Poitiers
Xavier LELEU, 05 49 44 37 17 ext. +33, xavier.leleu@chu-poitiers.fr
CH Cornouaille Quimper
Quimper
Ronan LE CALLOCH, 02 98 52 67 16 ext. +33, r.lecalloch@ch-cornouaille.fr
CH de Saint Nazaire
Saint-Nazaire
Marion LOIRAT, 02 72 27 83 22 ext. +33, m.loirat@ch-saintnazaire.fr
ICANS
Strasbourg
Cécile SONNTAG, 03 68 76 73 01 ext. +33, c.sonntag@icans.eu
CH Tarbes-Lourdes
Tarbes
Noémie GADAUD, 05 62 54 61 10 ext. +33, ngadaud@ch-tarbes-vic.fr
CHU Toulouse
Toulouse
Aurore PERROT, 05 31 15 64 90 ext. +33, perrot.aurore@iuct-oncopole.fr
CHRU Bretonneau
Tours
Thomas CHALOPIN, 02 47 47 37 12 ext. +33, t.chalopin@chu-tours.fr
CH Bretagne Atlantique
Vannes
Pascal GODMER, 02 97 01 41 45 ext. +33, pascal.godmer@ch-bretagne-atlantique.fr
About this study
Official title: A Multi-center, Open-label, Phase 2 Randomized Study of Elranatamab Plus Lenalidomide Versus Daratumumab Plus Lenalidomide as Post Transplantation Maintenance Therapy in Patients With Newly-diagnosed Myeloma. IFM 2024-06
Lenalidomide is a standard of care for maintenance therapy after autologous stem cell transplantation in newly diagnosed myeloma patients. Recently, two large phase 3 randomized trials demonstrated a progression free survival benefit with daratumumab maintenance post autologous stem cell transplantation. Bispecific antibodies targeting B-Cell Maturation Antigen are approved for the treatment of relapsed refractory myeloma patients after 3 prior lines of therapy including proteasome inhibitor, immunomodulator IMiD and anti CD38 monoclonal antibody. In the cohort A of the MAGNETISMM-3 phase 2 study (n=123), elranatamab single-agent demonstrated strong efficacy with favorable safety profile in patients with advanced multiple myeloma (median of 5 prior lines, 96% of patients with triple class refractory disease). Lenalidomide has been shown to promote cytotoxic activity of CD3 bispecific antibodies. 7We propose a phase 2 randomized study comparing elranatamab plus lenalidomide versus daratumumab plus lenalidomide for 2 years as post-transplant maintenance in patients with newly diagnosed multiple myeloma. The primary objective is minimal residual disease rate after one year of maintenance. Secondary objectives include Progression-Free Survival, safety, quality of life, return to work and overall survival.
Read the detailed description
Post transplant maintenance with daratumumab and lenalidomide is now considered a standard of care in transplant eligible newly diagnosed myeloma patients. The T-cell engager elranatamab is approved for relapsed myeloma patients, and is currently evaluated in frontline therapy. The combination of bispecific antibody with lenalidomide demosntrated promising response rates with favorable safety profile.
The phase 2 randomized study ELMMA aims to compare the efficacy and safety of elranatamab plus lenalidomide verus daratumumab plus lenalidomide for 2 years as post-transplant maintenance in newly diagnosed myeloma patients.
Target population: n=176, newly diagnosed myeloma transplant eligible following 4-6 cycles of quadruplet induction and autologous stem cell transplantation.
- Conditions
- Multiple Myeloma
- Being tested
- Elranatamab, Daratumumab, Lenalidomide
- Keywords
- Multiple Myeloma, maintenance, elranatamab, lenalidomide, daratumumab
- Medical subject headings
- Multiple Myeloma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ElranatamabDrug
Each injection may be up to 2 mL in volume; however, if the maximum volume allowed per institution's policy is lower than 2 mL, the number of injections may be increased to accommodate this difference in volume and ensure the correct dose is delivered. Elranatamab should be administered to the abdomen, with preference given to the lower quadrants when possible.
Each participant may receive study intervention for a maximum of 24 cycles.
DaratumumabDrug
1800 mg will be administrated every cycles
LenalidomideDrug
Daily administarted during 21 days, at each cycle
| Study group | Role | What they receive |
|---|---|---|
| Usual care : Daratumumab + Lenalidomide | Active comparator | Not described Receives: Drug: Daratumumab; Drug: Lenalidomide |
| Comparative treatment : Elranatamab + Lenalidomide | Experimental | Not described Receives: Drug: Elranatamab; Drug: Lenalidomide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Minimal Residual Disease negativity rate
Minimal Residual Disease negativity rate (10-6, NGS) status after 12 cycles of maintenance
Measured: At the beginning of cycle 13 (each cycle is 28 days)
Secondary outcomes (9)
Safety and tolerability of Dara-Len and Elra-Len
Presence and severity of Treatment-Emergent Adverse Events defined by National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (Number of Treatment-Emergent Adverse Events), except for Cytokine Release Syndrome and Immune effector Cell-Associated Neurotoxicity syndrome, which will be assessed based on American Society for Transplantation and Cellular Therapy guidelines.
Measured: 4 years
Progression-free survival
Progression-free survival, defined as the time from randomization to the first occurrence of Progressive Disease, or death from any cause, whichever occurs first. Subjects alive and for whom disease progression has not been observed will be censored at the last date of follow-up.
Measured: 4 years
Minimal Residual Disease negativity with the threshold evaluated at one year after randomisation
Rate of Minimal Residual Disease status at one year after randomisation
Measured: At the beginning of cycle 13 (each cycle is 28 days)
Minimal Residual Disease negativity with the threshold evaluated at one two years
Rate of Minimal Residual Disease status at two years after randomization
Measured: At the beginning of cycle 25 (each cycle is 28 days)
Sustained Minimal Residual Disease negativity
Rate of patients with Minimal Residual Disease negative status during at least 12 months (at least two consecutive times)
Measured: At the beginning of cycle 13 and 25 (each cycle is 28 days)
Complete Response or better
The rate of complete response or better as defined by International Myeloma Working Group 2016
Measured: 4 years
Overall survival
Time from randomisation to the date of death due to any cause. Subjects alive will be censored at the last date of follow-up.
Measured: 4 years
Progression-free survival 2
Time from randomization to either second line Progressive Disease (assessed by investigator on the first subsequent line of antimyeloma therapy) or death, whichever occurs first. Subjects alive and for whom a second disease progression has not been observed will be censored at the last date of follow-up.
Measured: 4 years
Ability of return to work
Ability of return to work assessed by a specific questionnaire
Measured: At the beginning of cycle 1 (each cycle is 28 days), at 3 months, 6 months, 12 months, 24 months, 36 months and 48 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Apr 2025
- Study start1 May 2025 (estimated)
- Primary completion30 Nov 2030 (estimated)
- Study completion30 Nov 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple MyelomaStudies of the same condition, open and under way.
- More trials run by Nantes University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 176 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Nantes University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06931704
- Sponsor's protocol ID
- RC23_0603
- Acronym
- IFM 2024_06
- Status last verified
- Apr 2025
- First submitted
- 1 Apr 2025
- Last updated
- 23 Apr 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 23 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-center, Open-label, Phase 2 Randomized Study of Elranatamab Plus Lenalidomide Versus Daratumumab Plus Lenalidomide as Post Transplantation Maintenance Therapy in Patients With Newly-diagnosed Myeloma. IFM 2024-06
- ClinicalTrials.gov ID
- NCT06931704
- Acronym / sponsor ID
- IFM 2024_06 / RC23_0603
- Conditions
- Multiple Myeloma
- Keywords
- Multiple Myeloma, maintenance, elranatamab, lenalidomide, daratumumab
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 176 participants (estimated)
- Lead sponsor
- Nantes University HospitalUniversity, hospital or other
- Study start
- 1 May 2025 (estimated)
- Primary completion
- 30 Nov 2030 (estimated)
- Study completion
- 30 Nov 2031 (estimated)
- First posted
- 17 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Lenalidomide is a standard of care for maintenance therapy after autologous stem cell transplantation in newly diagnosed myeloma patients. Recently, two large phase 3 randomized trials demonstrated a progression free survival benefit with daratumumab maintenance post autologous stem cell transplantation. Bispecific antibodies targeting B-Cell Maturation Antigen are approved for the treatment of relapsed refractory myeloma patients after 3 prior lines of therapy including proteasome inhibitor, immunomodulator IMiD and anti CD38 monoclonal antibody. In the cohort A of the MAGNETISMM-3 phase 2 study (n=123), elranatamab single-agent demonstrated strong efficacy with favorable safety profile in patients with advanced multiple myeloma (median of 5 prior lines, 96% of patients with triple class refractory disease). Lenalidomide has been shown to promote cytotoxic activity of CD3 bispecific antibodies. 7We propose a phase 2 randomized study comparing elranatamab plus lenalidomide versus daratumumab plus lenalidomide for 2 years as post-transplant maintenance in patients with newly diagnosed multiple myeloma. The primary objective is minimal residual disease rate after one year of maintenance. Secondary objectives include Progression-Free Survival, safety, quality of life, return to work and overall survival.
Detailed description
Post transplant maintenance with daratumumab and lenalidomide is now considered a standard of care in transplant eligible newly diagnosed myeloma patients. The T-cell engager elranatamab is approved for relapsed myeloma patients, and is currently evaluated in frontline therapy. The combination of bispecific antibody with lenalidomide demosntrated promising response rates with favorable safety profile.
The phase 2 randomized study ELMMA aims to compare the efficacy and safety of elranatamab plus lenalidomide verus daratumumab plus lenalidomide for 2 years as post-transplant maintenance in newly diagnosed myeloma patients.
Target population: n=176, newly diagnosed myeloma transplant eligible following 4-6 cycles of quadruplet induction and autologous stem cell transplantation.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Usual care : Daratumumab + Lenalidomide | Active comparator | Drug: Daratumumab, Drug: Lenalidomide |
| Comparative treatment : Elranatamab + Lenalidomide | Experimental | Drug: Elranatamab, Drug: Lenalidomide |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- - Male or female subjects, 18 years of age or older
- - Voluntary written informed consent must be given before performance of any study-related procedure not part of normal medical care, with the understanding that the subject may withdraw consent at any time without prejudice to future medical care.
- - Subject must have documented multiple myeloma according to International Myeloma Working Group (IMWG) criteria and have received 4 to 6 cycles of quadruplet-based therapy including proteasome inhibitor, IMID and anti CD38 monoclonal antibody.
- - Subject must have received only one line of therapy and achieved at least a partial response as per IMWG 2016 criteria.
- - Subject must have received high-dose melphalan and ASCT within 12 months of the start of induction therapy and be within 6 months of the last ASCT at the time of first treatment dose.
Key exclusion criteria (30 listed)
- - Subjects have received any prior anti BCMA therapy.
- - Subject have received post transplantation maintenance therapy.
- - Subject intolerant to lenalidomide or have discontinued treatment due to any AE related to lenalidomide.
- - Subject is exhibiting clinical signs of meningeal involvement of multiple myeloma.
- - Myocardial infarction within 6 months prior to enrollment according to NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ElranatamabEach injection may be up to 2 mL in volume; however, if the maximum volume allowed per institution's policy is lower than 2 mL, the number of injections may be increased to accommodate this difference in volume and ensure the correct dose is delivered. Elranatamab should be administered to the abdomen, with preference given to the lower quadrants when possible. Each participant may receive study intervention for a maximum of 24 cycles. | Drug | Comparative treatment : Elranatamab + Lenalidomide |
| Daratumumab1800 mg will be administrated every cycles | Drug | Usual care : Daratumumab + Lenalidomide |
| LenalidomideDaily administarted during 21 days, at each cycle | Drug | Comparative treatment : Elranatamab + Lenalidomide, Usual care : Daratumumab + Lenalidomide |
Primary outcome
Minimal Residual Disease negativity rate
Time frame: At the beginning of cycle 13 (each cycle is 28 days)
Minimal Residual Disease negativity rate (10-6, NGS) status after 12 cycles of maintenance
9 secondary outcomes
Safety and tolerability of Dara-Len and Elra-Len
Time frame: 4 years
Progression-free survival
Time frame: 4 years
Minimal Residual Disease negativity with the threshold evaluated at one year after randomisation
Time frame: At the beginning of cycle 13 (each cycle is 28 days)
Minimal Residual Disease negativity with the threshold evaluated at one two years
Time frame: At the beginning of cycle 25 (each cycle is 28 days)
Sustained Minimal Residual Disease negativity
Time frame: At the beginning of cycle 13 and 25 (each cycle is 28 days)
Complete Response or better
Time frame: 4 years
Overall survival
Time frame: 4 years
Progression-free survival 2
Time frame: 4 years
Ability of return to work
Time frame: At the beginning of cycle 1 (each cycle is 28 days), at 3 months, 6 months, 12 months, 24 months, 36 months and 48 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Apr 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Multiple Myeloma
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Active, not recruitingPhase 3
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Multiple Myeloma
Active, not recruitingPhase 1/2
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Multiple Myeloma
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
36 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Elranatamab, Daratumumab and Lenalidomide in people with Multiple Myeloma, run by Nantes University Hospital at 36 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 36 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Cyrille TOUZEAU (02 40 08 32 71, cyrille.touzeau@chu-nantes.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Minimal Residual Disease negativity rate (time frame: At the beginning of cycle 13 (each cycle is 28 days)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2025.